Amphastar Pharmaceuticals/$AMPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Ticker
$AMPH
Sector
Primary listing
Employees
2,028
Headquarters
Website
AMPH Metrics
BasicAdvanced
$1.2B
9.92
$2.68
0.80
-
Price and volume
Market cap
$1.2B
Beta
0.8
52-week high
$52.05
52-week low
$20.39
Average daily volume
437K
Financial strength
Current ratio
3.293
Quick ratio
2.139
Long term debt to equity
85.374
Total debt to equity
86.536
Interest coverage (TTM)
5.70%
Profitability
EBITDA (TTM)
236.73
Gross margin (TTM)
49.86%
Net profit margin (TTM)
18.64%
Operating margin (TTM)
25.14%
Effective tax rate (TTM)
16.77%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
7.31%
Return on equity (TTM)
18.32%
Valuation
Price to earnings (TTM)
9.921
Price to revenue (TTM)
1.758
Price to book
1.63
Price to tangible book (TTM)
6.9
Price to free cash flow (TTM)
11.556
Free cash flow yield (TTM)
8.65%
Free cash flow per share (TTM)
2.3
Growth
Revenue change (TTM)
1.37%
Earnings per share change (TTM)
-14.81%
3-year revenue growth (CAGR)
14.86%
10-year revenue growth (CAGR)
12.31%
3-year earnings per share growth (CAGR)
14.79%
10-year earnings per share growth (CAGR)
22.91%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
Bulls say / Bears say
BAQSIMI® sales increased 21% year-over-year to $46.5 million in Q2 2025, helping offset declines in other product lines and showing successful integration after the acquisition (Nasdaq)
In August 2025, Amphastar’s board authorized a $50 million boost to its share repurchase program, signaling management’s confidence in the company’s financial strength and future growth (SEC)
Amphastar began a multi-year plan to quadruple manufacturing capacity at its Rancho Cucamonga site, aiming to enhance operational stability and support upcoming proprietary and biosimilar product launches (TipRanks)
Net revenues decreased 4% year-over-year to $174.4 million in Q2 2025, mainly due to lower sales in several longstanding products, signaling near-term revenue headwinds (Nasdaq)
Gross margin declined to 49.6% from 52.2% in Q2 2025, reflecting competitive pricing challenges and the termination of previous transition service agreements (The Motley Fool)
Sales of important legacy products, Glucagon injection and Epinephrine, fell by 25% and 42% respectively in Q2 2025, illustrating fierce competition and market shifts towards alternative therapies (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
AMPH News
AllArticlesVideos
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
Accesswire1 month ago
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
Benzinga2 months ago
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Accesswire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amphastar Pharmaceuticals stock?
Amphastar Pharmaceuticals (AMPH) has a market cap of $1.2B as of October 07, 2025.
What is the P/E ratio for Amphastar Pharmaceuticals stock?
The price to earnings (P/E) ratio for Amphastar Pharmaceuticals (AMPH) stock is 9.92 as of October 07, 2025.
Does Amphastar Pharmaceuticals stock pay dividends?
No, Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Amphastar Pharmaceuticals dividend payment date?
Amphastar Pharmaceuticals (AMPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals (AMPH) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.